The information on this site is intended for healthcare professionals in the United States and is not intended for the general public.

i am a healthcare professional i am not a healthcare professional
JANUVIA® (sitagliptin) tablets

Nationwide formulary access

Greater than 80% of patients in commercial plans are covered at the lowest branded co-pay without prior authorizations.a,b

For Medicare Part D beneficiaries, approximately 90% are covered at the lowest branded co-pay without prior authorizations.a,b

Use the tool below to find local formulary coverage information.

1
2
3

aFormulary data provided by Fingertip Formulary®, April, 2014.
Percentages based on current enrollment.

bAmong oral antidiabetics and glucagon-like peptide-1s.

cIncludes commercial, Medicaid, and Medicare Part D plans.

Formulary status is believed to be accurate at the time of update but cannot be guaranteed. Formulary status for national plans may not reflect plan variation at the local level.

Updated formulary status information for Medicare plans may be available from the Centers for Medicare & Medicaid Services: www.medicare.gov.

View your results below for the county you chose in step 2.
Results are listed alphabetically.


A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z

Selected Important Risk Information
There have been postmarketing reports of acute pancreatitis, including fatal and nonfatal hemorrhagic or necrotizing pancreatitis, in patients taking JANUVIA. After initiating JANUVIA, observe patients carefully for signs and symptoms of pancreatitis. If pancreatitis is suspected, promptly discontinue JANUVIA and initiate appropriate management. It is unknown whether patients with a history of pancreatitis are at increased risk of developing pancreatitis while taking JANUVIA.

Assessment of renal function is recommended prior to initiating JANUVIA and periodically thereafter. A dosage adjustment is recommended in patients with moderate or severe renal insufficiency and in patients with end-stage renal disease requiring hemodialysis or peritoneal dialysis. Caution should be used to ensure that the correct dose of JANUVIA is prescribed.

There have been postmarketing reports of worsening renal function, including acute renal failure, sometimes requiring dialysis. A subset of these reports involved patients with renal insufficiency, some of whom were prescribed inappropriate doses of sitagliptin.

View Additional Selected Important Risk Information

Important Information

JANUVIA® (sitagliptin) tablets is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

JANUVIA should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.

JANUVIA has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk of developing pancreatitis while taking JANUVIA.

Before prescribing JANUVIA® (sitagliptin) tablets, please read the Prescribing Information. The Medication Guide also is available.

This site is intended for health care professionals of the United States, its territories, and Puerto Rico.

Copyright © 2013 Merck Sharp & Dohme Corp., a subsidiary of  Merck & Co., Inc. All rights reserved.

DIAB-1050515-0005 04/13